Impact of COVID-19 in patients with autoimmune bullous diseases: Report from an international registry.

• Authors: MEIJER Joost M; RASHID Hanan; VERGADI Styliani; ANTIGA Emiliano; VEZZOLI Pamela; BALESTRI Riccardo; PATSATSI Aikaterini; UZUN Soner; SKILJEVIC Dusan; JEDLIČKOVÁ Hana; VOJTĚCHOVÁ Lucia; CORRA Alberto; PONZIANI Alessandra; GÜNTHER Claudia; CIANCHINI Giuseppe; SCHEFZYK Matthias; MARZANO Angelo; GIOVANNI Di Zenzo; SHIMANOVICH Iakov; FAIRLEY Janet; MASCARÓ Jose M; CAPRONI Marzia; MAGLIE Roberto; SCHMIDT Enno; HORVÁTH Barbara
• Year of publication: 2023
• Type: Article in Periodical
• Magazine / Source: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
• MU Faculty or unit: Faculty of Medicine
• Web: https://onlinelibrary.wiley.com/doi/10.1111/jdv.19242
• Doi: http://dx.doi.org/10.1111/jdv.19242
• Keywords: COVID-19; autoimmune bullous diseases
• Description: For autoimmune bullous diseases (AIBD) such as bullous pemphigoid (BP) and pemphigus an increased risk of COVID-19 infection and mortality was reported, with oral prednisolone (dose ?10?mg/day) and treatment of rituximab being a risk factor. A population-based cohort study showed an increased COVID-19 associated mortality in patients with BP, but not in patients with pemphigus vulgaris. Here, we provide the findings of an international registry for health care providers about COVID-19 infection in patients with AIBD, reporting on timing and clinical presentation of COVID-19 infection, AIBD disease activity and outcome.